RY

163.23

+1.83%↑

TD

94.43

+2.23%↑

BMO

137.27

+2.76%↑

CM

95.94

+2.73%↑

BNS

70.16

+2.68%↑

RY

163.23

+1.83%↑

TD

94.43

+2.23%↑

BMO

137.27

+2.76%↑

CM

95.94

+2.73%↑

BNS

70.16

+2.68%↑

RY

163.23

+1.83%↑

TD

94.43

+2.23%↑

BMO

137.27

+2.76%↑

CM

95.94

+2.73%↑

BNS

70.16

+2.68%↑

RY

163.23

+1.83%↑

TD

94.43

+2.23%↑

BMO

137.27

+2.76%↑

CM

95.94

+2.73%↑

BNS

70.16

+2.68%↑

RY

163.23

+1.83%↑

TD

94.43

+2.23%↑

BMO

137.27

+2.76%↑

CM

95.94

+2.73%↑

BNS

70.16

+2.68%↑

Search

Houlihan Lokey Inc

Slēgts

SektorsFinanšu

143.37 1.39

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

141.18

Max

145.19

Galvenie mērījumi

By Trading Economics

Ienākumi

4.8M

117M

Pārdošana

58M

717M

P/E

Sektora vidējais

21.537

54.484

Dividenžu ienesīgums

1.7

Peļņas marža

16.253

Darbinieki

2,702

EBITDA

-10M

169M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+36.59% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

1.70%

4.92%

Nākamie ieņēmumi

2026. g. 6. maijs

Nākamais dividenžu datums

2026. g. 12. jūn.

Nākamais Ex dividenžu datums

2026. g. 1. jūn.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-3B

9.8B

Iepriekšējā atvēršanas cena

141.98

Iepriekšējā slēgšanas cena

143.37

Ziņu noskaņojums

By Acuity

83%

17%

403 / 441 Rangs Finance

Houlihan Lokey Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 31. marts 23:31 UTC

Karstas akcijas

Stocks to Watch: Nike, RH, NCino

2026. g. 31. marts 22:35 UTC

Peļņas

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

2026. g. 1. apr. 00:00 UTC

Iegādes, apvienošanās, pārņemšana

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

2026. g. 31. marts 23:50 UTC

Iegādes, apvienošanās, pārņemšana

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

2026. g. 31. marts 23:43 UTC

Tirgus saruna

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

2026. g. 31. marts 23:33 UTC

Tirgus saruna
Galvenie ziņu notikumi

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

2026. g. 31. marts 23:21 UTC

Peļņas

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

2026. g. 31. marts 23:14 UTC

Tirgus saruna
Peļņas

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

2026. g. 31. marts 23:12 UTC

Tirgus saruna

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

2026. g. 31. marts 22:36 UTC

Peļņas

China Vanke 2025 Loss Widens >000002.SZ

2026. g. 31. marts 22:36 UTC

Peļņas

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

2026. g. 31. marts 22:36 UTC

Peļņas

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

2026. g. 31. marts 22:36 UTC

Peļņas

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

2026. g. 31. marts 22:36 UTC

Peļņas

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

2026. g. 31. marts 21:46 UTC

Iegādes, apvienošanās, pārņemšana

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

2026. g. 31. marts 21:36 UTC

Tirgus saruna

West African Resources's Costs Higher Than Bull Expected -- Market Talk

2026. g. 31. marts 21:35 UTC

Peļņas

Nike Expects China Sales Down 20% in 4Q, CFO Says

2026. g. 31. marts 21:35 UTC

Peļņas

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

2026. g. 31. marts 21:35 UTC

Peļņas

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

2026. g. 31. marts 21:33 UTC

Iegādes, apvienošanās, pārņemšana

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

2026. g. 31. marts 21:33 UTC

Peļņas

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

2026. g. 31. marts 21:32 UTC

Peļņas

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

2026. g. 31. marts 21:28 UTC

Peļņas

Nike Expects to End 4Q With Elevated Inventory, CFO Says

2026. g. 31. marts 21:26 UTC

Peļņas

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

2026. g. 31. marts 21:25 UTC

Peļņas

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

2026. g. 31. marts 21:24 UTC

Tirgus saruna
Peļņas

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

2026. g. 31. marts 21:22 UTC

Peļņas

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

2026. g. 31. marts 21:22 UTC

Peļņas

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

2026. g. 31. marts 21:21 UTC

Peļņas

Nike's Digital Channel Still Too Promotional, CFO Says

2026. g. 31. marts 21:20 UTC

Peļņas

Nike CEO: Converse Remains Important to Portfolio

Salīdzinājums

Cenas izmaiņa

Houlihan Lokey Inc Prognoze

Cenas mērķis

By TipRanks

36.59% augšup

Prognoze 12 mēnešiem

Vidējais 196.17 USD  36.59%

Augstākais 214 USD

Zemākais 163 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Houlihan Lokey Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

6 ratings

4

Pirkt

2

Turēt

0

Pārdot

Noskaņojums

By Acuity

403 / 441 Rangs Finanšu

Ziņu noskaņojums

Ļoti spēcīga liecība "Lāču" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Houlihan Lokey Inc

Houlihan Lokey, Inc., an investment banking company, provides merger and acquisition (M&A), capital market, financial restructuring, and financial and valuation advisory services in the United States and internationally. It operates in three segments: Corporate Finance (CF), Financial Restructuring (FR), and Financial and Valuation Advisory (FVA). The CF segment offers general financial advisory services; and advises public and private institutions on buy-side and sell-side transactions, leveraged loans, private mezzanine debt, high-yield debt, initial public offerings, follow-ons, convertibles, equity private placements, private equity, and liability management transactions, as well as financial sponsors on various transactions. The FR segment advises debtors, creditors, and other parties-in-interest related to recapitalization/deleveraging transactions. This segment also provides a range of advisory services, including structuring, negotiation, and confirmation of plans of reorganization; structuring and analysis of exchange offers; corporate viability assessment; dispute resolution and expert testimony; and procuring debtor-in-possession financing. The FVA segment offers valuations of various assets, such as companies, illiquid debt and equity securities, and intellectual property; and dispute resolution services. This segment also provides fairness opinions in connection with M&A and other transactions, solvency opinions in connection with corporate spin-offs and dividend recapitalizations, and other types of financial opinions. The company serves corporations, financial sponsors, and government agencies. Houlihan Lokey, Inc. was incorporated in 1972 and is headquartered in Los Angeles, California.
help-icon Live chat